Condition
Kala Azar
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
2 treatments under study, led by Miltefosine Initially 25 Mgkgday For 28 Days
Research Leaders
9 sponsors active, led by Institute of Tropical Medicine, Belgium
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Phase 1/2 (1)
Trial Status
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Miltefosine Initially 25 Mgkgday For 28 Days1
- Long Lasting Impregnated Nets Llin1
Active Sponsors
- Institute of Tropical Medicine, Belgium1
- AEterna Zentaris1
- B.P. Koirala Institute of Health Sciences1
- Rajendra Memorial Research Institute of Medical Sciences1
- AB Foundation1
Top Investigators
Núcleo de Doenças Infecciosas - UFES
Prince Leopold Institute of Tropical Medicine in Antwerp (ITM), Belgium.
Institute of Medical Sciences of the Banaras Hindu University, India
Rajendra Memorial Research Institute of Medical Sciences
Centre for Health and Population Research (ICDDR,B), Dhaka, Bangladesh
Related Conditions
- Visceral Leishmaniasis1